Category : Pharmaceuticals And Healthcare | Published Date : Oct 2024 | Type : Press Release
In the newly published report Consegic Business Intelligence states that the Phenylketonuria Market size was valued at USD 820.57 Million in 2022 and is projected to reach USD 1,230.05 Million by 2030, growing at a CAGR of 5.2% from 2023 to 2030. Phenylketonuria (PKU) is a rare genetic disorder caused by a deficiency in the PAH gene, leading to the buildup of phenylalanine in the blood. This condition, if untreated, results in severe neurological issues. PKU management involves dietary restrictions and the use of specialized supplements and drugs to prevent phenylalanine accumulation.
The report comprises the Phenylketonuria Market Share, Size & Industry Analysis, By Type (Hyperphenylalaninemia, Mild PKU, Moderate and Variant, and Classic PKU), Product Type (Drugs (Kuvan, Pegavaliase, and Others), Nutritional Supplements, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2023-2030.
The report contains detailed information on Phenylketonuria Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profile, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
The increasing prevalence of phenylketonuria and advancements in genomics are key drivers of market growth. Additionally, increased R&D funding in bioinformatics presents growth opportunities.
Based on type, the market is segmented into hyperphenylalaninemia, mild PKU, moderate and variant, and classic PKU.
Based on product type, the market includes drugs, nutritional supplements, and others.
Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.
Based on regions, the global market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
Report Attributes | Report Details |
Study Timeline | 2017-2030 |
Market Size in 2031 | USD 1,230.05 Million |
CAGR (2024-2031) | 5.2% |
By Type | Hyperphenylalaninemia, Mild PKU, Moderate and Variant, Classic PKU |
By Product Type | Drugs (Kuvan, Pegavaliase, Others), Nutritional Supplements, Others |
By Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others |
By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Phenylketonuria Industry: